The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

AbbVie Inc

NYSE: ABBV
Last

(U.S.) $68.70

Today's change+0.64 +0.94%
Updated November 26 4:00 PM EST. Delayed by at least 15 minutes.
 

AbbVie Inc

NYSE: ABBV
Last

(U.S.) $68.70

Today's change+0.64 +0.94%
Updated November 26 4:00 PM EST. Delayed by at least 15 minutes.

AbbVie Inc Hits New 52-week High

AbbVie Inc closed up Wednesday by (U.S.)$0.64 or 0.94% to (U.S.)$68.70 and setting a new 52-week high. Over the last five days, shares have gained 4.89% and 30.09% year to date. Shares have outperformed the S&P 500 by 26.66% during the last year.

Key company metrics

  • Open(U.S.) $68.34
  • Previous close(U.S.) $68.06
  • High(U.S.) $68.86
  • Low(U.S.) $67.88
  • Bid / Ask-- / --
  • YTD % change+30.09%
  • Volume4,045,983
  • Average volume (10-day)6,192,412
  • Average volume (1-month)7,872,840
  • Average volume (3-month)13,138,014
  • 52-week range(U.S.) $45.50 to (U.S.) $68.86
  • Beta--
  • Trailing P/E29.78×
  • P/E 1 year forward20.79×
  • Forward PEG1.65×
  • Indicated annual dividend(U.S.) $1.96
  • Dividend yield2.85%
  • Trailing EPS(U.S.) $2.31
Updated November 26 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+18.92%

Based on its net profit margin of 18.92%, AbbVie Inc is less effective than other companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.77%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue5,0194,9264,5635,111
Total other revenue--------
Total revenue5,0194,9264,5635,111
Gross profit3,9553,8373,4753,829
Total cost of revenue1,0641,0891,0881,282
Total operating expense4,0593,4113,2123,576
Selling / general / administrative1,5951,4481,3401,448
Research & development812834772798
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)31516--48
Other operating expenses, total250------
Operating income9601,5151,3511,535
Interest income (expense), net non-operating-148-73-70-74
Gain (loss) on sale of assets--------
Other--------
Income before tax6871,4331,2861,439
Income after tax5061,0989801,128
Income tax, total181335306311
Net income5061,0989801,128
Total adjustments to net income--------
Net income before extra. items5061,0989801,128
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items5061,0989801,128
Inc. avail. to common incl. extra. items5061,0989801,128
Diluted net income5061,0989801,128
Dilution adjustment0------
Diluted weighted average shares1,6101,6081,6091,610
Diluted EPS excluding extraordinary itemsvalue per share0.310.680.610.70
Dividends per sharevalue per share0.420.420.400.40
Diluted normalized EPSvalue per share0.510.690.610.68